cell signaling technology 20473s (Cell Signaling Technology Inc)
Cell Signaling Technology Inc is a verified supplier 
Cell Signaling Technology Inc manufactures this product 
86
Structured Review
Cell Signaling Technology Inc
cell signaling technology 20473s
Cell Signaling Technology 20473s, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cell+signaling+technology+20473s/pm41700129-71-28-28
Average 86 stars, based on 1 article reviews
Cell Signaling Technology 20473s, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cell+signaling+technology+20473s/pm41700129-71-28-28
Average 86 stars, based on 1 article reviews
cell signaling technology 20473s - by Bioz Stars,
2026-10
86/100 stars
Images
Related Articles
Expressing:Article Title: Astrocytic PYGM attenuates tau pathology by promoting lactate-mediated neuroprotection. Article Snippet: .. To elucidate the underlying mechanisms and determine the feasibility of such a therapeutic strategy, additional studies are required and examples include: (1) revealing the regulatory mechanisms controlling astrocytic PYGM expression during tauopathy; (2) identifying the signaling pathways bywhich astrocytic PYGMactivity influences glial inflammatory responses, neuronal survival, and tau phosphorylation; (3) determining whether systemic metabolic modulators (e.g. PYGM activators) can safely augment astrocytic glycogen metabolism in vivo; (4) exploring whether similar mechanisms are operative in diverse tauopathies, such as progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). anti-p-Tau T181 (Cell Signaling Technology, 12885S, 1:1000), anti-pTau S199 (Invitrogen, 44734G, 1:1000), anti-p-Tau T205 (Biosource, 44-738G, 1:1000), anti-p-Tau T212 (Biosource, 44-740G, 1:1000), anti-p-Tau T231/S235 ( Protein-Protein interactions:Article Title: Astrocytic PYGM attenuates tau pathology by promoting lactate-mediated neuroprotection. Article Snippet: .. To elucidate the underlying mechanisms and determine the feasibility of such a therapeutic strategy, additional studies are required and examples include: (1) revealing the regulatory mechanisms controlling astrocytic PYGM expression during tauopathy; (2) identifying the signaling pathways bywhich astrocytic PYGMactivity influences glial inflammatory responses, neuronal survival, and tau phosphorylation; (3) determining whether systemic metabolic modulators (e.g. PYGM activators) can safely augment astrocytic glycogen metabolism in vivo; (4) exploring whether similar mechanisms are operative in diverse tauopathies, such as progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). anti-p-Tau T181 (Cell Signaling Technology, 12885S, 1:1000), anti-pTau S199 (Invitrogen, 44734G, 1:1000), anti-p-Tau T205 (Biosource, 44-738G, 1:1000), anti-p-Tau T212 (Biosource, 44-740G, 1:1000), anti-p-Tau T231/S235 ( Phospho-proteomics:Article Title: Astrocytic PYGM attenuates tau pathology by promoting lactate-mediated neuroprotection. Article Snippet: .. To elucidate the underlying mechanisms and determine the feasibility of such a therapeutic strategy, additional studies are required and examples include: (1) revealing the regulatory mechanisms controlling astrocytic PYGM expression during tauopathy; (2) identifying the signaling pathways bywhich astrocytic PYGMactivity influences glial inflammatory responses, neuronal survival, and tau phosphorylation; (3) determining whether systemic metabolic modulators (e.g. PYGM activators) can safely augment astrocytic glycogen metabolism in vivo; (4) exploring whether similar mechanisms are operative in diverse tauopathies, such as progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). anti-p-Tau T181 (Cell Signaling Technology, 12885S, 1:1000), anti-pTau S199 (Invitrogen, 44734G, 1:1000), anti-p-Tau T205 (Biosource, 44-738G, 1:1000), anti-p-Tau T212 (Biosource, 44-740G, 1:1000), anti-p-Tau T231/S235 ( In Vivo:Article Title: Astrocytic PYGM attenuates tau pathology by promoting lactate-mediated neuroprotection. Article Snippet: .. To elucidate the underlying mechanisms and determine the feasibility of such a therapeutic strategy, additional studies are required and examples include: (1) revealing the regulatory mechanisms controlling astrocytic PYGM expression during tauopathy; (2) identifying the signaling pathways bywhich astrocytic PYGMactivity influences glial inflammatory responses, neuronal survival, and tau phosphorylation; (3) determining whether systemic metabolic modulators (e.g. PYGM activators) can safely augment astrocytic glycogen metabolism in vivo; (4) exploring whether similar mechanisms are operative in diverse tauopathies, such as progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). anti-p-Tau T181 (Cell Signaling Technology, 12885S, 1:1000), anti-pTau S199 (Invitrogen, 44734G, 1:1000), anti-p-Tau T205 (Biosource, 44-738G, 1:1000), anti-p-Tau T212 (Biosource, 44-740G, 1:1000), anti-p-Tau T231/S235 ( other:Article Title: Astrocytic PYGM attenuates tau pathology by promoting lactate-mediated neuroprotection. Article Snippet: The nuclei were counterstained with 4′,6-diamidino-2phenylindole (DAPI) for 10 minutes, and the slides were mounted with anti-fade reagent (Boster Biological Technology, AP1109). |